| NCT ID | NCT06587165 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Weill Medical College of Cornell University |
| Condition | Tetralogy of Fallot With Pulmonary Stenosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-05-15 |
| Primary Completion | 2027-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2026-05-15 with a primary completion date of 2027-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Regenerative therapies could provide new ways of treating heart failure. Unlike many organs in the human body, such as the skin and the GI tract, the ability to regenerate heart muscle decreases after birth, but the precise timing of this decrease and how this decrease is altered in heart disease are uncertain. The investigators will use an innovative approach to quantify cellular heart regeneration in pediatric patients, an appropriate population for determining this decline as well as the potential for reactivating heart muscle regeneration. The study has now been registered on ClinicalTrials.gov, despite its initiation on July 23, 2015, as registration was not mandated at the original study site, the University of Pittsburgh Medical Center. However, following the transfer of the study to Weill Cornell Medicine, adherence to institutional requirements necessitated its registration on ClinicalTrials.gov.
Eligibility Criteria
Inclusion Criteria: * Patients at 30 days of age to 1 year of age undergoing scheduled elective cardiac surgery will be eligible for study inclusion. * The investigators will recruit patients at 30 days of age to 1 year of age with those types of heart disease whose surgical approach has a high probability of myocardial resection. * Diagnosis of ToF/PS or other types of heart disease that have a high likelihood of requiring surgery that involves routine resection of myocardium that becomes available for research Exclusion Criteria: * Patients with low chance of having resection of myocardium as part of their surgical care.
Contact & Investigator
Bernhard Kuhn, MD
PRINCIPAL INVESTIGATOR
Weill Medical College of Cornell University
Frequently Asked Questions
Who can join the NCT06587165 clinical trial?
This trial is open to participants of all sexes, aged 30 Days or older, up to 1 Year, studying Tetralogy of Fallot With Pulmonary Stenosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06587165 currently recruiting?
Yes, NCT06587165 is actively recruiting participants. Contact the research team at rab4029@med.cornell.edu for enrollment information.
Where is the NCT06587165 trial being conducted?
This trial is being conducted at New York, United States, New York, United States, Philadelphia, United States, Pittsburgh, United States.
Who is sponsoring the NCT06587165 clinical trial?
NCT06587165 is sponsored by Weill Medical College of Cornell University. The principal investigator is Bernhard Kuhn, MD at Weill Medical College of Cornell University. The trial plans to enroll 30 participants.